StockData
Niagen Bioscience, Inc. logo

Niagen Bioscience, Inc. (NAGE) stock

NAGENasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 14/3011% below fair value
$2.04+0.03 (+1.49%)

Close on Nov 17, 2026Market cap $161.42MP/E 17.0Yield –

Niagen Bioscience profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Niagen Bioscience's profit margin for the twelve months ending Sep 30, 2026 was 8.4%. For fiscal 2025 it was 13.4%, against 8.6% the year before. The highest annual figure on record is 13.4% in fiscal 2025.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202513.4%+4.8
FY2024Dec 31, 20248.6%+14.5
FY2023Dec 31, 2023-5.9%+17.0
FY2022Dec 31, 2022-23.0%+17.3
FY2021Dec 31, 2021-40.2%−6.6
FY2020Dec 31, 2020-33.6%+35.8
FY2019Dec 31, 2019-69.4%+36.1
FY2018Dec 31, 2018-105.6%−51.9
FY2017Dec 30, 2017-53.7%−40.2
FY2016Dec 31, 2016-13.5%+2.0
FY2015Jan 2, 2016-15.5%+19.7
FY2014Jan 3, 2015-35.2%+8.3
FY2013Dec 28, 2013-43.5%+57.0
FY2012Dec 29, 2012-100.4%−3.1
FY2011Dec 31, 2011-97.3%−70.2
FY2010Jan 1, 2011-27.1%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q3 FY2026Sep 30, 2026-4.3%−17.8
Q2 FY2026Jun 30, 20263.2%−8.4
Q1 FY2026Mar 31, 202620.1%+3.5
Q4 FY2025Dec 31, 202512.2%−12.4
Q3 FY2025Sep 30, 202513.5%+6.1
Q2 FY2025Jun 30, 202511.6%+11.7
Q1 FY2025Mar 31, 202516.6%+18.8
Q4 FY2024Dec 31, 202424.6%+24.1
Q3 FY2024Sep 30, 20247.3%+12.3
Q2 FY2024Jun 30, 2024-0.1%+10.7
Q1 FY2024Mar 31, 2024-2.2%+6.2
Q4 FY2023Dec 31, 20230.5%+7.3
Q3 FY2023Sep 30, 2023-4.9%+0.9
Q2 FY2023Jun 30, 2023-10.8%+27.5
Q1 FY2023Mar 31, 2023-8.4%+36.4
Q4 FY2022Dec 31, 2022-6.8%+23.2
Q3 FY2022Sep 30, 2022-5.8%+45.4
Q2 FY2022Jun 30, 2022-38.2%−6.8
Q1 FY2022Mar 31, 2022-44.8%+5.4
Q4 FY2021Dec 31, 2021-30.0%+9.5
Q3 FY2021Sep 30, 2021-51.2%−21.4
Q2 FY2021Jun 30, 2021-31.4%−7.2
Q1 FY2021Mar 31, 2021-50.3%−9.1
Q4 FY2020Dec 31, 2020-39.5%+28.2
Q3 FY2020Sep 30, 2020-29.7%+30.0
Q2 FY2020Jun 30, 2020-24.3%+45.6
Q1 FY2020Mar 31, 2020-41.1%+41.8
Q4 FY2019Dec 31, 2019-67.6%+23.0
Q3 FY2019Sep 30, 2019-59.8%+46.2
Q2 FY2019Jun 30, 2019-69.9%+33.3
Q1 FY2019Mar 31, 2019-83.0%+45.6
Q4 FY2018Dec 31, 2018-90.6%+26.5
Q3 FY2018Sep 30, 2018-106.0%−141.1
Q2 FY2018Jun 30, 2018-103.2%−55.0
Q1 FY2018Mar 31, 2018-128.6%−104.3
Q4 FY2017Dec 30, 2017-117.1%–
Q3 FY2017Sep 30, 201735.1%–
Q4 FY2016Dec 31, 2016-48.2%–
Q3 FY2016Oct 1, 2016-24.2%–

More Niagen Bioscience figures

See a number that looks wrong?